B of A Securities Upgrades Quest Diagnostics to Buy, Raises Price Target to $160
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Derik De Bruin upgraded Quest Diagnostics (NYSE:DGX) from Neutral to Buy and increased the price target from $140 to $160, indicating a positive outlook on the company's stock.
December 12, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quest Diagnostics was upgraded by B of A Securities from Neutral to Buy with a raised price target from $140 to $160, suggesting a bullish stance on the stock.
Upgrades by analysts, especially from neutral to buy, typically signal confidence in a company's future performance and can lead to increased investor interest and a potential rise in stock price. The raised price target further emphasizes the analyst's positive view on the stock's value.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100